Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib

Maxime Vanmechelen, Diether Lambrechts, Thomas Van Brussel, Annelies Verbiest, Gabrielle Couchy, Patrick Schöffski, Herlinde Dumez, Philip R. Debruyne, Evelyne Lerut, Jean Pascal Machiels, Vincent Richard, Maarten Albersen, Vincent Verschaeve, Stéphane Oudard, Arnaud Méjean, Pascal Wolter, Jessica Zucman-Rossi, Benoit Beuselinck*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

We describe a potential biomarker associated with progression-free survival and overall survival on sunitinib in metastatic clear-cell renal cell carcinoma. rs2981582 is a polymorphism in the fibroblast growth factor receptor 2. In our series of 154 patients treated with sunitinib, the TT-variant, present in 13% of the patients, was associated with shorter progression-free survival and overall survival.

Original languageEnglish
Pages (from-to)e235-e246
JournalClinical Genitourinary Cancer
Volume17
Issue number2
DOIs
Publication statusPublished - Apr 2019
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Urology

Keywords

  • Angiogenesis inhibitor
  • Biomarker
  • Outcome
  • Prognosis
  • Single nucleotide polymorphisms

Fingerprint

Dive into the research topics of 'Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib'. Together they form a unique fingerprint.

Cite this